Stock listing
NASDAQ:ZBIO Zenas BioPharma, Inc. Stock
Home listing (NASDAQ) of Zenas BioPharma, Inc.
Follow Zenas BioPharma, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ZBIO
$23.85 USD -2.57 (-9.7%)
Close on Nov 20, 2026
- Day range
- $23.78 – $25.64 USDNov 20, 2026
- Volume
- 579,893 sharesNov 20, 2026
- Market cap
- $1.62B USDAt the close on Nov 20, 2026 · price × 67.82M shares outstanding
- 52-week range
- $13.50 – $44.60 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $17.84M USDMedian day 527,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ZBIO · Home | $23.85 USD | -2.57 (-9.7%) | 579,893 | $24.75 | $25.64 | $23.78 | $26.42 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ZBIO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $23.85 | -2.57 | -9.7% | $24.75 | $25.64 | $23.78 | 579,893 | |
| $26.42 | -1.33 | -4.8% | $27.84 | $28.84 | $26.29 | 480,035 | |
| $27.75 | -0.18 | -0.6% | $27.93 | $28.13 | $27.00 | 524,652 | |
| $27.93 | -0.08 | -0.3% | $27.79 | $28.35 | $27.50 | 630,393 | |
| $28.01 | +0.37 | +1.3% | $27.50 | $28.18 | $26.89 | 304,825 | |
| $27.64 | -1.06 | -3.7% | $28.18 | $28.75 | $27.42 | 750,771 | |
| $28.70 | +0.12 | +0.4% | $28.95 | $29.51 | $28.50 | 306,259 | |
| $28.58 | +0.01 | 0.0% | $28.22 | $29.89 | $28.11 | 304,669 | |
| $28.57 | +0.31 | +1.1% | $28.75 | $30.02 | $27.80 | 634,856 | |
| $28.26 | +2.33 | +9.0% | $26.21 | $28.44 | $25.94 | 543,966 | |
| $25.93 | -2.53 | -8.9% | $28.10 | $28.49 | $25.79 | 822,021 | |
| $28.46 | +0.08 | +0.3% | $29.27 | $29.80 | $28.01 | 800,738 | |
| $28.38 | +0.76 | +2.8% | $27.85 | $29.05 | $27.84 | 572,811 | |
| $27.62 | -0.77 | -2.7% | $28.47 | $28.81 | $27.15 | 408,282 | |
| $28.39 | -0.37 | -1.3% | $28.35 | $29.11 | $27.91 | 358,069 | |
| $28.76 | -0.01 | 0.0% | $29.08 | $29.60 | $28.37 | 373,024 | |
| $28.77 | +1.47 | +5.4% | $27.10 | $29.07 | $27.03 | 391,455 | |
| $27.30 | +0.06 | +0.2% | $27.09 | $28.23 | $26.72 | 581,011 | |
| $27.24 | +0.37 | +1.4% | $27.18 | $28.17 | $26.68 | 371,646 | |
| $26.87 | -1.36 | -4.8% | $28.00 | $28.33 | $26.73 | 377,500 | |
| $28.23 | +0.15 | +0.5% | $27.95 | $28.83 | $27.51 | 406,000 | |
| $28.08 | -0.10 | -0.4% | $28.47 | $29.44 | $27.90 | 484,000 | |
| $28.18 | +1.47 | +5.5% | $26.38 | $29.71 | $26.38 | 549,000 | |
| $26.71 | +1.87 | +7.5% | $25.08 | $27.55 | $25.08 | 696,500 | |
| $24.84 | -0.56 | -2.2% | $25.36 | $25.96 | $24.51 | 661,700 | |
| $25.40 | +0.54 | +2.2% | $24.96 | $25.94 | $24.25 | 471,900 | |
| $24.86 | -0.30 | -1.2% | $24.82 | $26.49 | $24.39 | 425,100 | |
| $25.16 | -1.24 | -4.7% | $26.11 | $27.00 | $25.04 | 519,700 | |
| $26.40 | -0.86 | -3.2% | $26.93 | $27.49 | $26.30 | 602,500 | |
| $27.26 | +1.02 | +3.9% | $26.18 | $27.64 | $26.18 | 429,600 | |
| $26.24 | -1.94 | -6.9% | $27.98 | $27.98 | $25.51 | 557,500 | |
| $28.18 | +1.24 | +4.6% | $26.89 | $28.86 | $26.78 | 509,100 | |
| $26.94 | -0.89 | -3.2% | $27.87 | $28.14 | $26.28 | 357,600 | |
| $27.83 | -0.465 | -1.6% | $28.47 | $29.06 | $27.77 | 1,131,900 | |
| $28.30 | +0.355 | +1.3% | $28.47 | $29.20 | $27.84 | 1,513,600 | |
| $27.94 | +0.97 | +3.6% | $26.89 | $29.23 | $26.55 | 881,900 | |
| $26.97 | +0.21 | +0.8% | $26.99 | $28.38 | $26.54 | 623,200 | |
| $26.76 | -0.79 | -2.9% | $27.30 | $27.62 | $26.18 | 440,600 | |
| $27.55 | +0.60 | +2.2% | $27.07 | $28.23 | $26.46 | 615,300 | |
| $26.95 | -0.55 | -2.0% | $27.44 | $28.50 | $25.90 | 747,800 | |
| $27.50 | -2.13 | -7.2% | $29.51 | $30.12 | $25.70 | 962,900 | |
| $29.63 | -3.42 | -10.3% | $33.09 | $33.09 | $29.53 | 525,100 | |
| $33.05 | +0.50 | +1.5% | $32.55 | $33.84 | $32.15 | 452,800 | |
| $32.55 | +1.05 | +3.3% | $31.62 | $33.19 | $31.00 | 414,500 | |
| $31.50 | -0.47 | -1.5% | $32.04 | $32.04 | $31.25 | 2,515,200 | |
| $31.97 | -0.35 | -1.1% | $32.78 | $33.48 | $31.55 | 527,800 | |
| $32.32 | +0.39 | +1.2% | $31.89 | $33.23 | $31.59 | 746,400 | |
| $31.93 | +0.02 | +0.1% | $32.06 | $32.06 | $30.27 | 716,000 | |
| $31.91 | +0.79 | +2.5% | $31.00 | $32.00 | $30.66 | 634,600 | |
| $31.12 | +0.02 | +0.1% | $31.48 | $32.32 | $31.12 | 421,700 | |
| $31.10 | -1.19 | -3.7% | $31.88 | $31.89 | $30.73 | 646,900 | |
| $32.29 | -0.76 | -2.3% | $33.02 | $33.53 | $32.09 | 385,400 | |
| $33.05 | +0.17 | +0.5% | $32.65 | $33.84 | $32.31 | 441,200 | |
| $32.88 | -0.04 | -0.1% | $32.66 | $33.29 | $32.38 | 452,700 | |
| $32.92 | -0.21 | -0.6% | $33.42 | $33.66 | $32.37 | 515,100 | |
| $33.13 | +1.15 | +3.6% | $32.21 | $33.40 | $31.93 | 757,500 | |
| $31.98 | -0.34 | -1.1% | $32.20 | $32.73 | $31.55 | 432,300 | |
| $32.32 | +1.05 | +3.4% | $31.51 | $32.77 | $29.88 | 527,700 | |
| $31.27 | -1.35 | -4.1% | $32.27 | $32.38 | $31.19 | 439,100 | |
| $32.62 | -0.42 | -1.3% | $32.81 | $33.69 | $32.38 | 659,000 | |
| $33.04 | -0.73 | -2.2% | $33.80 | $33.99 | $31.91 | 651,600 | |
| $33.77 | +2.12 | +6.7% | $32.00 | $33.78 | $31.65 | 633,583 | |
| $31.65 | -0.64 | -2.0% | $32.40 | $32.48 | $30.95 | 481,882 | |
| $32.29 | +0.67 | +2.1% | $31.83 | $32.79 | $31.45 | 808,700 | |
| $31.62 | +0.37 | +1.2% | $30.72 | $32.20 | $29.50 | 1,172,500 |
- Ticker
- NASDAQ:ZBIO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Latest deck · 2026
Technical Presentation (2026)
Technical · 24 slides
Latest news
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 18, 2026
Closed $23.85 (-9.7%) on Nov 20, 2026
Zenas BioPharma Launches The Distance Between Platform to Bring Greater Visibility to the Hidden Burden of IgG4-Related Disease
Nov 17, 2026
Closed $27.75 (-0.6%) on Nov 17, 2026
Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference
Nov 9, 2026
Closed $28.57 (+1.1%) on Nov 9, 2026
Zenas BioPharma to Host Virtual R&D Event
Oct 6, 2026
Closed $26.94 (-3.2%) on Oct 6, 2026
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
Sep 22, 2026
Closed $33.05 (+1.5%) on Sep 22, 2026
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
Sep 8, 2026
Closed $33.05 (+0.5%) on Sep 8, 2026
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 13, 2026
Closed $29.20 (-6.7%) on Aug 13, 2026
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
Jun 2, 2026
Closed $17.40 (+1.6%) on Jun 3, 2026
Zenas BioPharma Announces Submission of Biologics License Application to U.S. FDA for Obexelimab in IgG4-RD
May 29, 2026
Closed $18.40 (-0.9%) on May 29, 2026
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
May 28, 2026
Closed $18.56 (+2.6%) on May 28, 2026
Zenas BioPharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 24 in the last 12 months · 35 in all · newest Nov 18, 2026 · oldest 2025
- Decks
- 4 decks · latest 2026
Where Zenas BioPharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ZBIO · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ZBIO | BOATS | United States | USD |
Valuation
EV/sales 114× against a median of 50.8×: 8th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.26B USD
- P/E
- Loss
- EV/sales
- 114×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 7.6×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 1.1×
- Beta vs S&P 500
- 1.05
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Zenas BioPharma, Inc. · NASDAQ:ZBIO | US$1.62B | US$1.26B | n/a | 114× | n/a | 7.6× | n/a | 1.1× | 1.05 |
| Neuren Pharmaceuticals Limited · ASX:NEU | US$1.76B | US$1.57B | 87.3× | 36.7× | 108× | 8.0× | 47.1% | 0.0× | n/a |
| Stoke Therapeutics, Inc. · NASDAQ:STOK | US$1.75B | US$1.43B | n/a | 50.8× | n/a | 5.0× | −862.1% | 0.0× | 0.78 |
| First Tracks Biotherapeutics, Inc. · NASDAQ:TRAX | US$1.75B | US$1.60B | n/a | n/a | n/a | 11.6× | n/a | 0.0× | 1.80 |
| Maze Therapeutics, Inc. · NASDAQ:MAZE | US$1.74B | US$1.39B | n/a | 69.6× | n/a | 4.1× | −757.4% | 0.1× | 0.66 |
| Lycia Therapeutics, Inc. · NASDAQ:LYCA | US$1.72B | US$1.60B | n/a | 237× | n/a | n/a | −540.9% | n/a | n/a |
| Hitgen Inc. Class A · SSE:688222 | US$1.55B | US$1.44B | 66.5× | 13.6× | n/a | 6.5× | 22.1% | 0.2× | n/a |
| Recursion Pharmaceuticals, Inc. · NASDAQ:RXRX | US$1.53B | US$987.7M | n/a | 14.5× | n/a | 1.7× | −697.1% | 0.0× | 2.83 |
| Alvotech · NASDAQ:ALVO | US$1.47B | US$2.78B | n/a | 5.7× | 31.4× | n/a | −36.5% | n/a | 0.90 |
| ABL Bio, Inc. · KRX:298380 | US$1.47B | US$1.34B | n/a | 52.7× | n/a | 11.5× | −229.4% | 0.0× | n/a |
| PELL Bio-Med Technology Co Ltd · TWSE:6949 | US$1.46B | US$1.40B | n/a | 1,591× | n/a | 18.7× | n/a | 0.1× | n/a |
| Median of the others | US$1.64B | US$1.43B | 76.9× | 50.8× | 69.5× | 7.3× | −385.1% | 0.0× | 0.90 |
Forecasts
7 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 47.88 USD · Analysts' mean
- EPS, year to Dec 2026
- -5.94 · 2 analysts
- Revenue, year to Dec 2026
- 20.38M · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Lonnie Moulder | Chief Executive Officer and Chairman of the Board of Directors |
| Joe Farmer | President and Chief Operating Officer |
| Jerald Korn | Chief Legal & Strategy Officer |
| Caroline Chevalier | Chief Administrative Officer |
| Haley Laken | Chief Scientific Officer |
| Heinrich Schlieker | Chief Technical Officer |
| Lisa von Moltke | Head of Research and Development and Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Lonnie Moulder | Chief Executive Officer and Chairman of the Board of Directors |
| Christy Oliger | Board Member |
| Hongbo Lu | Board Member |
| Jake Nunn | Board Member |
| James Boylan | Board Member |
| John Orloff | Board Member |
| Patricia Allen | Board Member |
| Patrick Enright | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −8.9% |
| Q2 2026 | Aug 13, 2026 · Before open | −6.7% |
| Q1 2026 | May 13, 2026 | −1.4% |
| Q4 2025 | Mar 16, 2026 · Before open | −3.4% |
| Q3 2025 | Nov 12, 2025 · Before open | +1.7% |
| Q2 2025 | Aug 12, 2025 · Before open | +6.7% |
| Q1 2025 | May 15, 2025 · Before open | +12.2% |
| Q4 2024 | Feb 26, 2025 | −5.8% |
| Q3 2024 | Nov 12, 2024 · Before open | −3.1% |
| Q2 2024 | Aug 22, 2024 · After close |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (2026) | Technical | 24 slides | 2026 |
| Merger or Acquisition (October 2025) | Merger or acquisition | 49 slides | Oct 8, 2025 |
| Investor Presentation (June 2025) | Investor deck | 25 slides | Jun 4, 2025 |
| Investor Presentation (December 2024) | Investor deck | 36 slides | Dec 2, 2024 |
Financings
| Raise | Date |
|---|---|
| Private placement of common stock Announced: about US$120M · US$19 a share · Jefferies +1 Dealers: Jefferies (co-lead), Evercore ISI (co-lead) Insiders: Certain directors and officers of the Company participate at a price of $20.85 per share | Oct 8, 2025 |
| Royalty funding (5.5% royalty on worldwide net sales of obexelimab) Announced: up to US$300M · Evercore Dealers: Evercore Buyers: Royalty Pharma plc (up to $300 million in funding in exchange for a 5.5% royalty on worldwide net sales of obexelimab) Use of proceeds: Obexelimab development and a potential IgG4-RD commercial launch in the first half of 2027, subject to FDA approval | Sep 2, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$17.00 a share on Sep 12, 2024.
- Price
- US$17.00 a share
- Shares offered
- 13,235,294 shares of common stock
- Offering size
- US$225 million
- Underwriters' option
- Up to 1,985,294 more shares
- Listing
- ZBIO on the Nasdaq Global Select Market
- Underwriters
- MORGAN STANLEY, JEFFERIES, CITIGROUP, GUGGENHEIM SECURITIES · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jan 25, 2024 |
| Filed publicly | Aug 22, 2024 |
| Amended once | Sep 6, 2024 |
| Shares registered with an exchange | Sep 10, 2024 |
| Declared effective by the SEC | Sep 12, 2024 |
| Final prospectus, with the price | Sep 13, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 13, 2024 |
| EFFECT · Notice that a registration is effective | Sep 12, 2024 |
| S-1MEF · Registration of more shares for the same offering | Sep 12, 2024 |
| CERT · Exchange's certificate of listing | Sep 12, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 10, 2024 |
| CORRESP · Letter to the SEC | Sep 10, 2024 |
| CORRESP · Letter to the SEC | Sep 10, 2024 |
| S-1/A · Registration statement, amended | Sep 6, 2024 |
| CORRESP · Letter to the SEC | Aug 27, 2024 |
| S-1 · Registration statement | Aug 22, 2024 |
All 24 filings
| Filing | Filed |
|---|---|
| DRSLTR · Letter to the SEC with a draft | Jul 25, 2024 |
| UPLOAD · Letter from the SEC | Jul 24, 2024 |
| DRSLTR · Letter to the SEC with a draft | Jul 16, 2024 |
| UPLOAD · Letter from the SEC | Jul 5, 2024 |
| DRSLTR · Letter to the SEC with a draft | Jun 26, 2024 |
| DRS/A · Draft registration statement, amended | Jun 26, 2024 |
| UPLOAD · Letter from the SEC | Jun 18, 2024 |
| DRSLTR · Letter to the SEC with a draft | Jun 14, 2024 |
| DRS/A · Draft registration statement, amended | Jun 14, 2024 |
| UPLOAD · Letter from the SEC | May 28, 2024 |
| DRS/A · Draft registration statement, amended | May 16, 2024 |
| DRSLTR · Letter to the SEC with a draft | May 15, 2024 |
| UPLOAD · Letter from the SEC | Feb 21, 2024 |
| DRS · Draft registration statement | Jan 25, 2024 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 13, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 10.0M | 5.00M | 50.0M | 0 |
| Cost of revenue | 56.0K | 139.1M | 113.0K | 61.7M |
| Gross profit | 10.0M | -134.1M | 50.0M | -61.7M |
| Research and development | 168.1M | 139.1M | 60.0M | 62.7M |
| Selling, general and administrative | 53.3M | 28.8M | 17.1M | 12.8M |
| Operating income | -383.1M | -163.9M | -37.1M | -76.2M |
| Depreciation and amortization | 56.0K | 137.0K | 113.0K | 78.0K |
| EBITDA | -383.0M | -163.8M | -37.0M | -76.1M |
| Interest expense | 7.33M | 0 | ||
| Income before tax | -377.8M | -156.6M | -36.8M | -119.3M |
| Income tax | -79.0K | 429.0K | 301.0K | |
| Net income | -377.7M | -157.0M | -37.1M | -119.3M |
| Earnings per share, basic | -8.44 | -11.89 | -24.25 | -3.11 |
| Earnings per share, diluted | -8.44 | -11.89 | -24.25 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 110.6M | 319.7M | 56.9M | 67.2M |
| Short-term investments | 232.6M | 31.0M | 0 | |
| Current assets | 351.2M | 355.9M | 59.8M | 68.4M |
| Property, plant and equipment | 34.0K | 185.0K | 193.0K | |
| Total assets | 383.6M | 370.0M | 68.2M | 74.6M |
| Accounts payable | 7.11M | 17.1M | 5.40M | 5.82M |
| Current liabilities | 62.6M | 57.3M | 23.3M | 26.0M |
| Long-term debt | 78.6M | 20.3M | ||
| Total debt | 78.6M | 1.00M | 21.1M | 1.53M |
| Total liabilities | 141.5M | 57.5M | 43.8M | 266.9M |
| Shareholders' equity | 242.1M | 312.5M | -225.7M | -192.3M |
| Shares outstanding | 54.5M | 41.8M | 1.58M | 38.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -172.3M | -119.7M | -30.5M | -65.7M |
| Capital spending | -18.0K | -131.0K | -17.0K | -2.20M |
| Free cash flow | -172.4M | -119.8M | -30.5M | -67.8M |
| Cash from investing | -251.9M | -30.6M | -17.0K | -2.20M |
| Cash from financing | 215.3M | 413.0M | 20.1M | 59.4M |
| Share buybacks | 276.0K | |||
| Change in cash | -209.2M | 262.9M | -10.4M | -8.50M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 6, 2026 | Current report | SEC |
| 424B5 · Prospectus | Nov 6, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 13, 2026 | Current report | SEC |
| S-3ASR · Registration statement | Sep 11, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Sep 11, 2026 | Offer document | SEC |
All 196 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Sep 8, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Sep 8, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Sep 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 2, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 19, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 17, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| SCHEDULE 13D · Big-stake notice | May 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 2, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 31, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Mar 30, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Mar 30, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Mar 27, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Mar 27, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Mar 26, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Mar 26, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Mar 26, 2026 | Offer document | SEC |
| DEFA14A · Additional proxy material | Mar 16, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Mar 16, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 16, 2026 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 16, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 16, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 16, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 13, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 424B7 · Prospectus | Jan 28, 2026 | Offer document | SEC |
| SCHEDULE 13D · Big-stake notice | Jan 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 5, 2026 | Results | SEC |
| S-8 · Registration statement for employee plans | Dec 19, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 15, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Oct 27, 2025 | Current report | SEC |
| S-3ASR · Registration statement | Oct 21, 2025 | Offer document | SEC |
| 3 · Initial statement of ownership | Oct 15, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 9, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 9, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 9, 2025 | Insider trade | SEC |
| S-3ASR · Registration statement | Oct 8, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 8, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Sep 8, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 2, 2025 | Acquisition or disposal | SEC |
| S-8 · Registration statement for employee plans | Aug 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2025 | Management or board change | SEC |
| SCHEDULE 13D · Big-stake notice | Jun 6, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 4, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Apr 28, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 1, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Mar 21, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 11, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 11, 2025 | Annual report | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 5, 2025 | Results | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 2, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Oct 21, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Sep 25, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Sep 23, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Sep 23, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Sep 23, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2024 | Insider trade | SEC |
| SEC STAFF LETTER | Sep 18, 2024 | Other filings | SEC |
| 4/A · Change in ownership, amended | Sep 17, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Sep 16, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 16, 2024 | Current report | SEC |
| 424B4 · Prospectus | Sep 13, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 13, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Sep 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 12, 2024 | Insider trade | SEC |
| S-1MEF · Registration of more shares for the same offering | Sep 12, 2024 | Offer document | SEC |
| CERT · Exchange's certificate of listing | Sep 12, 2024 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Sep 10, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 10, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 10, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 6, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Aug 27, 2024 | Other filings | SEC |
| S-1 · Registration statement | Aug 22, 2024 | Offer document | SEC |
| DRSLTR · Letter to the SEC with a draft | Jul 25, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 24, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Jul 16, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 5, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Jun 26, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Jun 26, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 18, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Jun 14, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Jun 14, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 28, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | May 15, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | May 15, 2024 | Offer document | SEC |
| D | May 14, 2024 | Other filings | SEC |
| SEC STAFF LETTER | Feb 27, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 21, 2024 | Other filings | SEC |
| DRS · Draft registration statement | Jan 25, 2024 | Offer document | SEC |
| D | Nov 15, 2022 | Other filings | SEC |
Cap table
Built by 6ix from Zenas BioPharma, Inc.’s releases · as of Nov 16, 2026
- Common shares
- 67,817,793
- Fully diluted
- 68,051,793
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 67,817,793 | Oct 30, 2026 |
| Options and RSUs | 234,000 | Nov 16, 2026 |
Warrants and options
| Lot |
|---|
| Stock options · US$27.93 · expire about Nov 2036 |
| RSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 67,817,793 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christy Oliger Other companies: Bicara Therapeutics Inc. (Director · Since at least Jul 28, 2026); Nuvalent, Inc. (Director · Since at least Jun 18, 2025); LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); Vera Therapeutics, Inc. (Director · Since at least Jun 7, 2024); Replimune Group, Inc. (Director · Since at least Dec 1, 2021); Karyopharm Therapeutics Inc. (Director · Since at least Aug 28, 2020); RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Sierra Oncology Inc (Director · Jun 2, 2021 – Jul 1, 2022 · Past); Reata Pharmaceuticals Inc (Director · Apr 15, 2021 – Sep 26, 2023 · Past) | Director · Since at least Aug 13, 2026 |
| Leon O Moulder Jr Other companies: Zai Lab Ltd. (Director · Since at least Jan 1, 2021); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – May 23, 2024 · Past); Trevena, Inc. (Director · May 16, 2018 – Jun 15, 2023 · Past); Tesaro Inc (Chief Executive Officer, Director · Mar 1, 2018 – Jan 22, 2019 · Past) | See Remarks, Director · Since at least Sep 12, 2024 |
| James Boylan Other companies: CAMP4 Therapeutics Corporation (Director · Since at least Oct 10, 2024); Immunome, Inc. (Director · Since at least Oct 2, 2023); Compass Therapeutics, Inc. (Director · Since at least Nov 4, 2022) | Director · Since at least Sep 12, 2024 |
| Jason Raleigh Nunn Other companies: Addex Therapeutics Ltd (Director · Since at least Mar 18, 2026); Regulus Therapeutics Inc (Director · Since at least Jun 6, 2019); Trevena, Inc. (Director · May 16, 2019 – Jun 13, 2024 · Past) | Director · Since at least Sep 12, 2024 |
| Jennifer Fox Other companies: Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); ProKidney Corp. (Director · Since at least Jul 11, 2022); Nuvation Bio Inc. (Chief Financial Officer · Feb 10, 2021 – Feb 28, 2023 · Past) | See Remarks · Since at least Sep 12, 2024 |
| Hongbo Lu Other companies: Terns Pharmaceuticals, Inc. (Director · Since at least Jun 10, 2024); Arrowhead Pharmaceuticals, Inc. (Director · Since at least Mar 15, 2024) | Director · Since at least Sep 12, 2024 |
| Lisa von Moltke Other companies: Tvardi Therapeutics, Inc. (Director · Nov 1, 2022 – Jun 4, 2024 · Past); Seres Therapeutics, Inc. (See Remarks · Apr 6, 2020 – Feb 15, 2025 · Past) | Head of Research and Development and Chief Medical Officer · Since at least Mar 17, 2025 |
| Jake Nunn Other companies: Addex Therapeutics Ltd (Director · Since at least Jun 5, 2026) | Board Member · Since at least Nov 4, 2026 |
| Lonnie Moulder Other companies: Zai Lab Ltd. (Board Member · Since at least Nov 5, 2026) | Chief Executive Officer and Chairman of the Board of Directors · Since at least Aug 13, 2026 |
| Patrick Enright Other companies: Vera Therapeutics, Inc. (Managing Director, Longitude Capital · Since at least Nov 5, 2026) | Board Member · Since at least Nov 5, 2026 |
All 20 people
| Person | Seat |
|---|---|
| Caroline Chevalier | Chief Administrative Officer · Since at least Nov 4, 2026 |
| Haley Laken | Chief Scientific Officer · Since at least Apr 7, 2025 |
| Heinrich Schlieker | Chief Technical Officer · Since at least Nov 4, 2026 |
| Jerald Korn | Chief Legal & Strategy Officer · Since at least Nov 4, 2026 |
| Joe Farmer | President and Chief Operating Officer · Since at least Aug 13, 2026 |
| John Orloff | Board Member · Since at least Nov 5, 2026 |
| Matthew Osborne | Investor Relations and Corporate Communications · Mar 17, 2025 – Nov 4, 2026 · Past |
| Orlando Oliveira | See Remarks · Since at least Sep 12, 2024 |
| Patricia Allen | Director · Since at least Jun 10, 2025 |
| Zenas BioPharma | Royalty Pharma Investor Relations and Communications · Sep 2, 2025 – Nov 4, 2026 · Past |
Log in to ask 6ix AI your own questions about Zenas BioPharma, Inc.